Edgar Filing: Foundation Medicine, Inc. - Form 4

Foundation Form 4	Medicine, Inc.											
March 05, 2	_										PROVAL	
FORM	/1 4 UNITED	STATES						NGE CO	OMMISSION	OMB Number:	3235-0287	
Check this box										Expires:	January 31,	
if no lon subject t Section Form 4	AENT OF	F CHAN	HANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							2005 verage rs per 0.5		
Form 5 obligatio may cor <i>See</i> Instr 1(b).	ons Section 17(a) of the H	Public U	tility	Hol	ding Cor	npan	•	Act of 1934, 935 or Section			
(Print or Type	Responses)											
Miller Vincent A. Symbol				er Name and Ticker or Trading ation Medicine, Inc. [FMI]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3. Date o					est T	ransaction		(Check				
	ND STREET, C/C FION MEDICINE		(Month/I 03/03/2	-	ar)			- - b	Director _X Officer (give t elow) Chief M		Owner r (specify r	
CAMPDIC	(Street)		4. If Ame Filed(Mo			ate Origina r)	1	A	 Individual or Joi Applicable Line) X_ Form filed by Or Form filed by Mo 	ne Reporting Per	rson	
CAMBRIL	OGE, MA 02141							F	Person			
(City)	(State)	(Zip)	Tab	le I - N	on-l	Derivative	Secu	rities Acqui	red, Disposed of,	or Beneficial	ly Owned	
1.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)				3. 4. Securities Acquired (A) Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				(D)	Followingor IndirectReported(I)Transaction(s)(Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
C				Code	V	Amount	(D)	Price	(Instr. 3 and 4)			
Common Stock	03/03/2015			Μ		14,058	Α	\$ 0.84	113,120	D		
Common Stock	03/03/2015			М		3,000	А	\$ 0.84	116,120	D		
Common Stock	03/03/2015			S <u>(1)</u>		17,058	D	\$ 47.8143 (2)	99,062	D		
Common Stock	03/03/2015			М		4,813	А	\$ 0.84	103,875	D		

Μ

5,467 A \$4.16 109,342

D

Common

Stock

03/03/2015

Edgar Filing: Foundation Medicine, Inc. - Form 4

Common Stock	03/03/2015	М	3,125	А	\$ 7.12	112,467	D
Common Stock	03/03/2015	М	2,348	А	\$ 29.94	114,815	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	TransactionDerivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
stock option (right to buy)	\$ 0.84	03/03/2015		М	14,058	<u>(3)</u>	01/10/2022	Common Stock	14,058	
stock option (right to buy)	\$ 0.84	03/03/2015		М	7,813	<u>(4)</u>	01/10/2022	Common Stock	7,813	
stock option (right to buy)	\$ 4.16	03/03/2015		М	5,467	(5)	03/07/2023	common stock	5,467	
stock option (right to buy)	\$ 7.12	03/03/2015		М	3,125	<u>(6)</u>	05/21/2023	common stock	3,125	
stock option (right to buy)	\$ 29.94	03/03/2015		М	2,348	(7)	04/09/2024	common stock	2,348	

8 E S ()

Reporting Owners

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
Miller Vincent A. 150 SECOND STREET C/O FOUNDATION MEDICINE, INC. CAMBRIDGE, MA 02141			Chief Medical Officer				
Signatures							
Robert W. Hesslein, as Attorney-in-Fact f Miller	for Vince	nt A.	03/05/2015				

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The sale reported in this Form 4 was effected to cover the tax liabilities of the reporting person in connection with the exercise of the (1) stock options referenced herein. The reporting person exercised such stock options in order to participate in the tender offer commenced by Roche Holdings, Inc. on February 2, 2015.

Date

The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$47.75 to \$48.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the

- (2) Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- (3) This option was granted on January 10, 2012 and vests in equal quarterly installments beginning on December 31, 2012 until fully vested on September 30, 2016.
- (4) This option was granted on January 10, 2012 and vests in equal quarterly installments beginning on December 31, 2013 until fully vested on September 30, 2017.
- (5) This option was granted on March 7, 2013 and vests in equal quarterly installments beginning June 7, 2013 until fully vested on March 7, 2017.
- (6) This option was granted on May 21, 2013 and vests in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018.
- (7) This option was granted on April 9, 2014 and vests in equal quarterly installments beginning June 30, 2014 until fully vested on March 31, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.